Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient
Abstract
Pembrolizumab, an immune checkpoint inhibitor (ICI) targeting the programmed cell death protein 1 (PD-1) receptor on T cells, enhances the immune system’s ability to recognize and attack cancer cells. However, immune-related adverse events (irAEs) may arise, necessitating careful monitoring during treatment. Here, we present the case of a 47-year-old woman who developed multiple irAEs following pembrolizumab therapy. Initially diagnosed with Stage IIIB non-small cell lung cancer, she underwent chemotherapy followed by concurrent chemoradiotherapy. After two years of monitoring, progression of disease was observed, and pembrolizumab was initiated as second-line chemotherapy. Shortly thereafter, she presented with left-sided ptosis and weakness in both upper and lower extremities. Diagnostic evaluation, including a tensilon test and laboratory findings, confirmed with myositis, hepatitis, and myasthenia gravis. Treatment with steroids and neostigmine led to marked clinical improvement. Two months later, the patient developed additional dermatological symptoms, including rash and pruritus. Skin biopsy confirmed a diagnosis of pityriasis lichenoides. she is currently receiving antihistamines therapy, with no further exacerbation. This case underscores the importance of recognizing and promptly managing irAEs associated with ICIs to ensure patient safety and treatment efficacy.
##plugins.themes.bootstrap3.article.details##
Pembrolizumab, Immune-related adverse events (irAE), Immune-mediated hepatitis, Myasthenia gravis, Myositis, Pityriasis lichenoides chronica (PLC), Non-small cell lung cancer (NSCLC)
2. Zhou YJ, Li G, Wang J, et al. PD-L1: expression regulation. Blood Sci. 2023 Jan 13;5(2):77-91. doi: 10.1097/BS9.0000000000000149. PMID: 37228770; PMCID: PMC10205351.
3. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. PMID: 27718847.
4. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. PMID: 26558876; PMCID: PMC4892769.
5. Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020 May 7;6(1):38. doi: 10.1038/s41572-020-0160-6. PMID: 32382051; PMCID: PMC9728094.
6. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019 Nov 15;7(1):306. doi: 10.1186/s40425-019-0805-8. PMID: 31730012; PMCID: PMC6858629.
7. Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. J Autoimmun. 2019 Nov;104:102310. doi: 10.1016/j.jaut.2019.102310. PMID: 31421963.
8. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481. PMID: 29320654.
9. Khalid F, Gupta R, Gor R, et al. Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy. World J Oncol. 2023 Apr;14(2):109-118. doi: 10.14740/wjon1575. Epub 2023 Apr 30. PMID: 37188042; PMCID: PMC10181423.
10. Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis. Front Neurol. 2020 Jul 16;11:634. doi: 10.3389/fneur.2020.00634. PMID: 32765397; PMCID: PMC7378376.
11. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016 Dec 29;375(26):2570-2581. doi: 10.1056/NEJMra1602678. PMID: 28029925.
12. Geller L, Antonov NK, Lauren CT, Morel KD, Garzon MC. Pityriasis Lichenoides in Childhood: Review of Clinical Presentation and Treatment Options. Pediatr Dermatol. 2015 Sep-Oct;32(5):579-92. doi: 10.1111/pde.12581. Epub 2015 Mar 26. PMID: 25816855.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.